KALA BIO (KALA) Competitors $8.95 -0.26 (-2.81%) As of 03:13 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KALA vs. CRGX, PRQR, ACIU, MNPR, VYGR, GNFT, LYEL, VTYX, HRTX, and OGIShould you be buying KALA BIO stock or one of its competitors? The main competitors of KALA BIO include CARGO Therapeutics (CRGX), ProQR Therapeutics (PRQR), AC Immune (ACIU), Monopar Therapeutics (MNPR), Voyager Therapeutics (VYGR), GENFIT (GNFT), Lyell Immunopharma (LYEL), Ventyx Biosciences (VTYX), Heron Therapeutics (HRTX), and Organigram Global (OGI). These companies are all part of the "pharmaceutical products" industry. KALA BIO vs. Its Competitors CARGO Therapeutics ProQR Therapeutics AC Immune Monopar Therapeutics Voyager Therapeutics GENFIT Lyell Immunopharma Ventyx Biosciences Heron Therapeutics Organigram Global KALA BIO (NASDAQ:KALA) and CARGO Therapeutics (NASDAQ:CRGX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation. Do institutionals & insiders believe in KALA or CRGX? 24.6% of KALA BIO shares are owned by institutional investors. Comparatively, 93.2% of CARGO Therapeutics shares are owned by institutional investors. 8.3% of KALA BIO shares are owned by insiders. Comparatively, 2.9% of CARGO Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has better valuation and earnings, KALA or CRGX? KALA BIO is trading at a lower price-to-earnings ratio than CARGO Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKALA BION/AN/A-$38.51M-$6.79-1.32CARGO TherapeuticsN/AN/A-$167.50M-$4.64-0.96 Do analysts rate KALA or CRGX? KALA BIO currently has a consensus target price of $13.00, indicating a potential upside of 45.24%. CARGO Therapeutics has a consensus target price of $15.40, indicating a potential upside of 244.52%. Given CARGO Therapeutics' higher possible upside, analysts clearly believe CARGO Therapeutics is more favorable than KALA BIO.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score KALA BIO 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00CARGO Therapeutics 1 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.86 Does the media favor KALA or CRGX? In the previous week, CARGO Therapeutics had 4 more articles in the media than KALA BIO. MarketBeat recorded 4 mentions for CARGO Therapeutics and 0 mentions for KALA BIO. KALA BIO's average media sentiment score of 1.34 beat CARGO Therapeutics' score of 0.19 indicating that KALA BIO is being referred to more favorably in the media. Company Overall Sentiment KALA BIO Positive CARGO Therapeutics Neutral Is KALA or CRGX more profitable? CARGO Therapeutics' return on equity of -43.21% beat KALA BIO's return on equity.Company Net Margins Return on Equity Return on Assets KALA BION/A -686.43% -76.81% CARGO Therapeutics N/A -43.21%-37.26% Which has more risk & volatility, KALA or CRGX? KALA BIO has a beta of -1.81, meaning that its share price is 281% less volatile than the S&P 500. Comparatively, CARGO Therapeutics has a beta of 0.3, meaning that its share price is 70% less volatile than the S&P 500. SummaryCARGO Therapeutics beats KALA BIO on 8 of the 13 factors compared between the two stocks. Get KALA BIO News Delivered to You Automatically Sign up to receive the latest news and ratings for KALA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KALA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KALA vs. The Competition Export to ExcelMetricKALA BIOMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$63.05M$3.06B$5.76B$9.75BDividend YieldN/A2.24%4.40%4.10%P/E Ratio-1.3221.0030.8325.91Price / SalesN/A392.25469.77121.46Price / CashN/A43.2325.7828.79Price / Book4.439.739.466.03Net Income-$38.51M-$54.08M$3.27B$265.29M7 Day Performance4.32%3.12%2.37%2.86%1 Month Performance10.64%4.57%3.88%1.23%1 Year Performance48.94%10.22%30.52%19.11% KALA BIO Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KALAKALA BIO4.0578 of 5 stars$8.95-2.8%$13.00+45.2%+53.2%$63.05MN/A-1.3230Positive NewsCRGXCARGO Therapeutics2.1846 of 5 stars$4.47+0.1%$15.40+244.9%N/A$215.93MN/A-0.96116Analyst UpgradePRQRProQR Therapeutics2.8101 of 5 stars$2.04+0.8%$8.00+292.9%+5.6%$214.21M$20.46M-4.43180ACIUAC Immune1.6315 of 5 stars$2.11-1.1%$12.00+469.8%-30.2%$213.37M$31.02M-3.66140Positive NewsMNPRMonopar Therapeutics2.741 of 5 stars$33.96-5.3%$60.00+76.7%+1,147.5%$210.82MN/A-10.2610Gap UpVYGRVoyager Therapeutics3.9366 of 5 stars$3.76+0.9%$13.25+252.8%-49.6%$209.01M$80M-2.04100GNFTGENFIT2.1425 of 5 stars$4.17+1.5%$13.00+211.8%-0.8%$208.50M$76.77M0.00120Positive NewsGap UpLYELLyell Immunopharma3.7293 of 5 stars$10.75-0.1%$15.00+39.5%-65.5%$207.56M$60K-0.44270Positive NewsVTYXVentyx Biosciences2.2128 of 5 stars$2.86-4.8%$7.50+162.7%+21.2%$205.02MN/A-1.7130HRTXHeron Therapeutics4.2154 of 5 stars$1.33-1.9%$4.50+239.6%-28.2%$204.64M$144.29M-66.75300Positive NewsOGIOrganigram Global0.384 of 5 stars$1.51-3.5%N/A-20.8%$201.72M$117.47M30.11860 Related Companies and Tools Related Companies CARGO Therapeutics Competitors ProQR Therapeutics Competitors AC Immune Competitors Monopar Therapeutics Competitors Voyager Therapeutics Competitors GENFIT Competitors Lyell Immunopharma Competitors Ventyx Biosciences Competitors Heron Therapeutics Competitors Organigram Global Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KALA) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KALA BIO, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KALA BIO With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access